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Pneumocystis pneumonia (PCP) is one of the most frequent causes of mortality among 
HIV-infected patients. Primaquine (PQ) is an antimalarial 8-aminoquinoline effective 
against PCP when given in combination with clindamycin. This has drawn the attention 
of Medicinal Chemists towards the anti-PCP activity of 8-aminoquinolines, not only 
confined to those exhibiting antimalarial activity [1]. It is thought that anti-PCP  
8-aminoquinolines exert their anti-PCP activity by acting on the electronic transport and 
redox system of the P. carinii pathogen [1]. Recently, our research group has been 
developing imidazolidin-4-one derivatives of PQ (Scheme 1), targeting novel 
compounds with improved therapeutic action, namely, higher resistance to metabolic 
inactivation, lower toxicity and equal or higher antimalarial activity than that of the 
parent drug [2,3]. These imidazolidin-4-ones were seen to block the transmission of 
rodent malaria, caused by Plasmodium berghei on BalbC mice, to the mosquito vector 
Anopheles stephensi [3]. 
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Scheme 1. Synthetic route to primaquine imidazolidin-4-ones 
1) N-Boc-protected amino acid dicyclohexilcarbodiimide, 1-hydroxybenzotriazole; 2) i. neat trifluoroacetic 
acid; ii. Na2CO3; 3) propanone or a cyclic symmetrical ketone (cyclopentanone, cyclohexanone and 
cycloheptanone); CH3OH (reflux); triethylamine; 4 Å molecular sieves. 
 
The anti-PCP activity of our PQ derivatives is now under study and preliminary in vitro 
assays [4] show that some of the compounds exhibit slight to moderate activity after a 
72 h incubation period against P. carinii. In one case, the IC50 was comparable to that 
of parent PQ. Both these studies and forthcoming results from ongoing biological 
assays will be presented and discussed. 
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